Press release content from PR Newswire. The AP news staff was not involved in its creation.
Hillenbrand Announces Definitive Agreement to Sell ABEL Pumps to IDEX Corporation
January 11, 2021 GMT
Hillenbrand - a global diversified industrial company. (PRNewsfoto/Hillenbrand, Inc.)
BATESVILLE, Ind., Jan. 11, 2021 /PRNewswire/ Hillenbrand, Inc. (NYSE: HI) announced today that it has reached a definitive agreement to sell Abel Pumps, L.P., and certain of its affiliates (ABEL) to IDEX Corporation (NYSE: IEX). The sale follows Hillenbrand’s previously announced intent to exit the ABEL business.
Hillenbrand has entered into a Share and Interest Purchase and Transfer Agreement with IDEX, pursuant to which IDEX has agreed to acquire ABEL for $103.5 million in cash, subject to customary post-closing adjustments. The transaction is expected to be completed in Hillenbrand’s second fiscal quarter, subject to customary closing conditions.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and .
EpiPharma LLC; Cyclolab Plc.January 11, 2021 GMT
SZEGED, Hungary and BUDAPEST, Hungary, Jan. 11, 2021 (GLOBE NEWSWIRE) Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development company, today announced that the companies have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 .
Aadi Bioscience Inc.January 11, 2021 GMT
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China
EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China
Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties
PACIFIC PALISADES, CALIFORNIA and SHANGHAI, CHINA – January 11, 2021. Aadi Bioscience (Aadi), a biopharmaceutical company focusing on precision therapies for genomically defined cancers and EOC Pharma (EOC), a leading oncology specialty biopharmaceutical company in China, today jointly announced an exclusive license agreement for the development and commercialization of ABI-009 (FYARRO) in Greater China including mainland China, Ho
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank
Affimed N.V.January 11, 2021 GMT
€10 million available at closing and up to €15 million available upon achievement of certain milestones
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has entered into a debt financing agreement with Silicon Valley Bank German Branch (SVB) which provides Affimed with up to €25 million in term loans.
“We are pleased to continue our relationship with Silicon Valley Bank,” commented Angus Smith, Chief Financial Officer of Affimed. “This financing will help support the broad development strategy for our ICE® molecules as monotherapies and in combination with natural killer cells and checkpoint inhibitors.